Breaux  Castleman net worth and biography

Breaux Castleman Biography and Net Worth

Castleman joined Isis’ Board of Directors in June 2013. Castleman is President and Chief Executive Officer of Syntiro Healthcare Services, Inc., currently a health care investment company, having recently sold its operations as a service provider of integrated care management and disease management. Castleman is also a Director of USMD Holdings,Inc and a Senior Advisor to McNally Capital LLC in Chicago. Castleman serves as a Director of FemPartners, Inc., and a Senior Advisor to Match Point Partners LLC in New York.
Previously, he held positions as chairman of Mela Sciences, Inc., Director of Med Direct, Inc., President of the Scripps Clinic, President of Caremark International’s Physician Resource Group, and Chief Executive Officer of the Kelsey-Seybold Clinic.

Prior to that Castleman was the Head of the Houston office of Booz Allen & Hamilton (now Booz & Co.).

Castleman received a BA in economics from Yale University and attended New York University Graduate School of Business Administration. He has published articles on management issues in business and technical periodicals, including the Harvard Business Review, and has presented numerous papers and presentations to industry groups in energy, banking, healthcare, and agribusiness.

What is Breaux Castleman's net worth?

The estimated net worth of Breaux Castleman is at least $1.09 million as of June 25th, 2020. Mr. Castleman owns 25,183 shares of Ionis Pharmaceuticals stock worth more than $1,091,683 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Castleman may own. Learn More about Breaux Castleman's net worth.

How do I contact Breaux Castleman?

The corporate mailing address for Mr. Castleman and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Breaux Castleman's contact information.

Has Breaux Castleman been buying or selling shares of Ionis Pharmaceuticals?

Breaux Castleman has not been actively trading shares of Ionis Pharmaceuticals in the last ninety days. Most recently, Breaux Castleman sold 10,000 shares of the business's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $60.00, for a transaction totalling $600,000.00. Following the completion of the sale, the director now directly owns 25,183 shares of the company's stock, valued at $1,510,980. Learn More on Breaux Castleman's trading history.

Who are Ionis Pharmaceuticals' active insiders?

Ionis Pharmaceuticals' insider roster includes C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Ionis Pharmaceuticals?

During the last year, insiders at the sold shares 28 times. They sold a total of 288,471 shares worth more than $14,210,660.41. The most recent insider tranaction occured on February, 16th when CEO Brett P Monia sold 387 shares worth more than $17,217.63. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.

Information on this page was last updated on 2/16/2024.

Breaux Castleman Insider Trading History at Ionis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/25/2020Sell10,000$60.00$600,000.0025,183View SEC Filing Icon  
See Full Table

Breaux Castleman Buying and Selling Activity at Ionis Pharmaceuticals

This chart shows Breaux Castleman's buying and selling at Ionis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals logo
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
Read More

Today's Range

Now: $43.35
Low: $43.32
High: $44.95

50 Day Range

MA: $46.70
Low: $42.03
High: $52.01

2 Week Range

Now: $43.35
Low: $34.32
High: $54.44

Volume

1,967,194 shs

Average Volume

1,209,431 shs

Market Capitalization

$6.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4